Novogenia AG, an international healthcare company specializing in human genetics and personalized products, has announced the U.S. market launch of its new MGT Plus methylation test. This launch, in partnership with 10X Health, marks a significant expansion of their joint product pipeline and strengthens their international collaboration in genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions in the human body. It influences the processing of biological molecules such as vitamins and neurotransmitters. While commercially available tests typically analyze a limited number of genes, MGT Plus covers 27 genes, offering a more comprehensive view of methylation processes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, and vascular, immune, and cellular health.
Dr. Daniel Wallerstorfer, CEO of Novogenia AG, emphasized the test’s significance: “With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes. The significantly expanded scope of analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways, creating new opportunities for more personalized prevention and health strategies.” He added that the collaboration with 10X Health underscores their commitment to making scientific innovations accessible internationally.
The global direct-to-consumer testing market is growing rapidly. In 2025, it reached approximately $4.7 billion and is projected to exceed $16.0 billion by 2033. Genetic testing represents the largest segment, accounting for over 40% of the market. North America leads this sector, contributing around 50% of global market volume in 2025. This growth is driven by increasing consumer interest in personalized health information and preventive care.
Novogenia, headquartered in Munich, Germany, conducts genetic analyses in its own laboratory, which are used in disease diagnosis, treatment, and prevention, as well as in the production of tailored nutritional supplements and cosmetics. The company also supports physicians, therapists, and nutritionists by analyzing genetic predispositions to optimize patient care. Additionally, Novogenia holds investments in innovative biotech, healthcare, and life sciences companies.
For more information about Novogenia and its products, visit https://novogenia.com/novogenia-ag.
